Ofatumumab
- Level
- Commodity
- Parent
- 51111700
- Below
- 0
- Links · KBLI
- 8
Definition
UNSPSC 51111756This classification denotes a monoclonal antibody with the molecular formula C6480H10022N1742O2020S44, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier M95KG522R0, more generally known as ofatumumab. European Medicines Agency schedules ofatumumab in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB25221. The term OFATUMUMAB is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 20, no. 1, 2006, list 55. OFATUMUMAB is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule Ofatumumab under HS 30021091 and SITC 54163. SMILES:. As of Q4 2014, OFATUMUMAB remains the US FDA Preferred Term for this commodity. . Ofatumumab bears US NLM identifiers UMLS ID C1832027 and NCI Concept Code C66952.
Same parent
Under 51111700 · 67Activities that produce or sell this
KBLI · 8Inherited from family 51110000.
Warning
The links were generated with a large language model (Gemini 3.5 Flash), matching UNSPSC at the family level to KBLI at the kelompok level. Some of them maybe are wrong, so check any link you intend to rely on.